Corient Private Wealth LLC Acquires 5,305 Shares of Insmed, Inc. $INSM

Corient Private Wealth LLC lifted its stake in Insmed, Inc. (NASDAQ:INSM) by 34.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 20,865 shares of the biopharmaceutical company’s stock after purchasing an additional 5,305 shares during the period. Corient Private Wealth LLC’s holdings in Insmed were worth $3,631,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. CIBC Private Wealth Group LLC lifted its stake in Insmed by 42.1% in the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 53 shares during the period. CoreCap Advisors LLC purchased a new position in Insmed during the 4th quarter valued at about $27,000. GraniteShares Advisors LLC bought a new stake in shares of Insmed in the 4th quarter valued at about $30,000. Reflection Asset Management purchased a new stake in shares of Insmed in the 4th quarter worth approximately $30,000. Finally, Raiffeisen Bank International AG bought a new position in shares of Insmed during the fourth quarter valued at approximately $32,000.

Insmed Stock Performance

Shares of INSM stock opened at $103.38 on Friday. The company has a current ratio of 4.47, a quick ratio of 4.10 and a debt-to-equity ratio of 0.80. Insmed, Inc. has a 12-month low of $90.39 and a 12-month high of $212.75. The business’s 50 day moving average is $112.90 and its two-hundred day moving average is $143.82. The company has a market capitalization of $22.41 billion, a P/E ratio of -17.98 and a beta of 0.79.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.76) EPS for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.14. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The business had revenue of $305.96 million during the quarter, compared to analysts’ expectations of $300.81 million. During the same period in the previous year, the business earned ($1.42) earnings per share. The business’s revenue was up 229.7% compared to the same quarter last year. Analysts expect that Insmed, Inc. will post -2.55 EPS for the current fiscal year.

Insider Activity at Insmed

In other news, CEO William Lewis sold 21,398 shares of Insmed stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $103.32, for a total value of $2,210,841.36. Following the sale, the chief executive officer owned 258,917 shares in the company, valued at $26,751,304.44. This trade represents a 7.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Roger Adsett sold 88,060 shares of the business’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $164.63, for a total transaction of $14,497,317.80. Following the sale, the chief operating officer directly owned 106,810 shares of the company’s stock, valued at $17,584,130.30. This represents a 45.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 172,987 shares of company stock valued at $25,286,564. 2.10% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on INSM. Wells Fargo & Company lowered their target price on shares of Insmed from $177.00 to $160.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Barclays increased their price objective on Insmed from $231.00 to $237.00 and gave the company an “overweight” rating in a report on Wednesday, April 1st. Cantor Fitzgerald reissued an “overweight” rating on shares of Insmed in a research report on Wednesday, June 10th. Royal Bank Of Canada dropped their target price on Insmed from $205.00 to $195.00 and set an “outperform” rating on the stock in a research note on Friday, June 5th. Finally, Leerink Partners increased their price target on Insmed from $210.00 to $215.00 and gave the company an “outperform” rating in a research note on Tuesday, March 24th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $211.86.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.